Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
75.11
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews
↗
February 04, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.
↗
February 03, 2025
A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.
Via
Chartmill
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.
↗
February 03, 2025
Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.
Via
Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
↗
January 27, 2025
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Via
Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
↗
January 24, 2025
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
↗
January 15, 2025
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Via
Investor's Business Daily
Analyst Expectations For Halozyme Therapeutics's Future
↗
January 13, 2025
Via
Benzinga
9 Analysts Have This To Say About Halozyme Therapeutics
↗
December 18, 2024
Via
Benzinga
Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?
↗
December 18, 2024
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
BridgeBio Pharma Stock Earns 87 RS Rating
↗
January 14, 2025
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
Via
Investor's Business Daily
SpringWorks Therapeutics Stock Gets A RS Rating Lift
↗
January 08, 2025
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Via
Investor's Business Daily
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
↗
January 06, 2025
Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
↗
January 03, 2025
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
↗
December 16, 2024
NASDAQ:HALO, a growth stock which is not overvalued.
Via
Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
↗
December 13, 2024
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
Via
Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
↗
December 11, 2024
Via
Benzinga
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views
↗
November 20, 2024
Via
Benzinga
Looking Into Halozyme Therapeutics's Recent Short Interest
↗
November 05, 2024
Via
Benzinga
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
↗
November 22, 2024
Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.
Via
Benzinga
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
↗
November 22, 2024
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
November 22, 2024
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued.
Via
Chartmill
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
↗
November 15, 2024
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.
Via
Benzinga
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
↗
November 01, 2024
Via
Benzinga
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
↗
October 30, 2024
Via
Benzinga
Unveiling 12 Analyst Insights On Halozyme Therapeutics
↗
October 25, 2024
Via
Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
↗
November 01, 2024
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
↗
November 01, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 31, 2024
Via
Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
↗
October 31, 2024
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
Via
Chartmill
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
↗
October 22, 2024
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.